Iconic Photography and Ironic Geography: NATO Chief Launches First Fifth-Generation Aircraft Carrier antiwar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from antiwar.com Daily Mail and Mail on Sunday newspapers.
‘Ridiculous for Biden to customize a 90-day scientific probe on virus origins
Cao Siqi Published: May 28, 2021 12:01 AM
In this March 19, 2020, file photo laboratory scientist Andrea Luquette cultures coronavirus to prepare for testing at U.S. Army Medical Research and Development Command at Fort Detrick in Frederick, Md., where scientists are working to help develop solutions to prevent, detect and treat the coronavirus. Photo: AP
Despite US President Joe Biden showing his resolve to find out whether the coronavirus emerged from human contact with an infected animal or from a laboratory accident in a latest attempt to hype the virus-leakage conspiracy theory, scientists and foreign affairs experts from the US and China said they do not expect a credible report from the untrustworthy US intelligence community in 90 days as it is not a scientific institution at all.
/PRNewswire/ Inhalon Biopharma, a start-up immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute.
by WRAL TechWire May 26, 2021 .
DURHAM –Inhalon Biopharma is developing a “muco-trapping” antibody platform that could be used to treat acute respiratory infections, including COVID-19, and the Durham-based startup has now been awarded a $7 million contract by the United States Army Medical Research & Development Command (USAMRDC).
The contract will allow the company to conduct a placebo-controlled Phase 1 and Phase 2a study of its technology in COVID-19 outpatients, the company shared in a statement.
The technology, currently designated IN-006, is described by the company as a potent, neutralizing monoclonal antibody that is being investigated as a possible treatment for COVID-19.
The company expects results of the study in 2022.
Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled Muco-trapping Antibody for the Treatment of COVID-19 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.